Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-0350
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1 ; day:1 ; month:6 ; year:2022 ; pages:1-5
Child's nervous system ; (1.6.2022), 1-5
- Urheber
-
Cantor, Evan
Meyer, Ashley
Morris, Stephanie M.
Weisenberg, Judith L. Z.
Brossier, Nicole M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00381-022-05571-y
- URN
-
urn:nbn:de:101:1-2022073110280367037163
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cantor, Evan
- Meyer, Ashley
- Morris, Stephanie M.
- Weisenberg, Judith L. Z.
- Brossier, Nicole M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos
Activation of kappa opioid receptors reduces seizure activity in a dose-dependent way
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Lymphoproliferative malignancies in patients with neurofibromatosis 1
Analysis of two cases with bronchopulmonary neurofibromatosis
Neurofibromatosis type 1 with three synchronous tumors
Revisiting dandy–Walker malformation with associated neurofibromatosis
Constipation in adults with neurofibromatosis type 1
Kaposiform lymphangiomatosis effectively treated with MEK inhibition
A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos
Activation of kappa opioid receptors reduces seizure activity in a dose-dependent way
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Lymphoproliferative malignancies in patients with neurofibromatosis 1
Analysis of two cases with bronchopulmonary neurofibromatosis
Neurofibromatosis type 1 with three synchronous tumors
Revisiting dandy–Walker malformation with associated neurofibromatosis
Constipation in adults with neurofibromatosis type 1
Kaposiform lymphangiomatosis effectively treated with MEK inhibition
A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos
Activation of kappa opioid receptors reduces seizure activity in a dose-dependent way
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Lymphoproliferative malignancies in patients with neurofibromatosis 1
Analysis of two cases with bronchopulmonary neurofibromatosis
Neurofibromatosis type 1 with three synchronous tumors
Revisiting dandy–Walker malformation with associated neurofibromatosis
Constipation in adults with neurofibromatosis type 1